NervGen's NVG-291 Demonstrates Genuine Neural Recovery in Spinal Cord Injury Study
NGEN is trading near its 52-week low of $2.02 (7.4% above the low) on elevated volume (33× avg).
Summary
NervGen Pharma reported positive results from independent, blinded biomechanical gait analyses for its lead drug candidate, NVG-291, in a Phase 1b/2a spinal cord injury study. The data demonstrated a statistically significant treatment effect, indicating 'genuine neural recovery' in lower-body locomotor function. This strong clinical validation follows recent FDA alignment for NVG-291's registrational study and a $60 million public offering to fund its development. The positive efficacy data is critical for the company, which has faced recent 'going concern' warnings and cash runway concerns. NervGen plans to advance NVG-291 into a Phase 3 registrational study.
At the time of this announcement, NGEN was trading at $2.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $168.3M. The 52-week trading range was $2.02 to $6.30. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.